Evommune, Inc. (EVMN)vsBeiGene, Ltd. (ONC)
EVMN
Evommune, Inc.
$11.59
+3.02%
HEALTHCARE · Cap: $409.17M
ONC
BeiGene, Ltd.
$313.77
-0.71%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 57292% more annual revenue ($5.74B vs $10.00M). ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
EVMN
Avoid30
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVMN.
Margin of Safety
+81.0%
Fair Value
$1847.00
Current Price
$313.77
$1533.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EVMN
The strongest argument for EVMN centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : EVMN
The primary concerns for EVMN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
EVMN profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (54/100 vs 30/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evommune, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in this critical sector. With a promising pipeline and advanced research methodologies, Evommune is positioned to enhance immune response and improve patient outcomes. The company aims to establish a leading presence in the evolving immunotherapy market through its commitment to robust scientific practices and strategic partnerships. As it progresses through clinical trials, Evommune is striving to deliver transformative solutions that could redefine the standards of care in immunology, thereby significantly impacting patient quality of life.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?